[Primary treatment of Parkinson's disease: the application of the March 2000 consensus rules in the Nord Pas-de-Calais area].
Identifieur interne : 000E75 ( PubMed/Checkpoint ); précédent : 000E74; suivant : 000E76[Primary treatment of Parkinson's disease: the application of the March 2000 consensus rules in the Nord Pas-de-Calais area].
Auteurs : C. Simonin ; L. Defebvre ; A. DestéeSource :
- Revue neurologique [ 0035-3787 ] ; 2004.
Descripteurs français
- Wicri :
- geographic : France.
English descriptors
- KwdEn :
- MESH :
- geographic : France.
- drug therapy : Parkinson Disease.
- statistics & numerical data : Guideline Adherence.
- Aged, Consensus Development Conferences as Topic, Female, Humans, Male, Middle Aged, Practice Guidelines as Topic, Retrospective Studies.
Abstract
For Parkinson's disease, the choice of the initial treatment is essentially between L-Dopa and dopaminergic agonists. Selegilin, anticholinergic and amantadine can be used for subjects with moderate symptoms. The first French consensus conference, held in 2000, elaborated decision-making rules which take into account both the age and disease severity. The aim of our study was to evaluate the impact of these recommendations on treatments prescribed for de novo parkinsonian patients in the Nord-Pas de Calais area, comparing initial prescriptions before and after the conference.
PubMed: 15602362
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15602362Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Primary treatment of Parkinson's disease: the application of the March 2000 consensus rules in the Nord Pas-de-Calais area].</title><author><name sortKey="Simonin, C" sort="Simonin, C" uniqKey="Simonin C" first="C" last="Simonin">C. Simonin</name><affiliation><nlm:affiliation>Service de Neurologie et Pathologie du Mouvement, Clinique Neurologique, EA 2683, CHRU, Lille.</nlm:affiliation><wicri:noCountry code="subField">Lille</wicri:noCountry></affiliation></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15602362</idno><idno type="pmid">15602362</idno><idno type="wicri:Area/PubMed/Corpus">000F85</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000F85</idno><idno type="wicri:Area/PubMed/Curation">000F45</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000F45</idno><idno type="wicri:Area/PubMed/Checkpoint">000F45</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000F45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Primary treatment of Parkinson's disease: the application of the March 2000 consensus rules in the Nord Pas-de-Calais area].</title><author><name sortKey="Simonin, C" sort="Simonin, C" uniqKey="Simonin C" first="C" last="Simonin">C. Simonin</name><affiliation><nlm:affiliation>Service de Neurologie et Pathologie du Mouvement, Clinique Neurologique, EA 2683, CHRU, Lille.</nlm:affiliation><wicri:noCountry code="subField">Lille</wicri:noCountry></affiliation></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name></author><author><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Consensus Development Conferences as Topic</term><term>Female</term><term>France</term><term>Guideline Adherence (statistics & numerical data)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Practice Guidelines as Topic</term><term>Retrospective Studies</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>France</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Guideline Adherence</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Consensus Development Conferences as Topic</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Practice Guidelines as Topic</term><term>Retrospective Studies</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>France</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">For Parkinson's disease, the choice of the initial treatment is essentially between L-Dopa and dopaminergic agonists. Selegilin, anticholinergic and amantadine can be used for subjects with moderate symptoms. The first French consensus conference, held in 2000, elaborated decision-making rules which take into account both the age and disease severity. The aim of our study was to evaluate the impact of these recommendations on treatments prescribed for de novo parkinsonian patients in the Nord-Pas de Calais area, comparing initial prescriptions before and after the conference.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15602362</PMID><DateCreated><Year>2004</Year><Month>12</Month><Day>16</Day></DateCreated><DateCompleted><Year>2005</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0035-3787</ISSN><JournalIssue CitedMedium="Print"><Volume>160</Volume><Issue>12</Issue><PubDate><Year>2004</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Revue neurologique</Title><ISOAbbreviation>Rev. Neurol. (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Primary treatment of Parkinson's disease: the application of the March 2000 consensus rules in the Nord Pas-de-Calais area].</ArticleTitle><Pagination><MedlinePgn>1164-70</MedlinePgn></Pagination><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">For Parkinson's disease, the choice of the initial treatment is essentially between L-Dopa and dopaminergic agonists. Selegilin, anticholinergic and amantadine can be used for subjects with moderate symptoms. The first French consensus conference, held in 2000, elaborated decision-making rules which take into account both the age and disease severity. The aim of our study was to evaluate the impact of these recommendations on treatments prescribed for de novo parkinsonian patients in the Nord-Pas de Calais area, comparing initial prescriptions before and after the conference.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Three groups of 50 patients whose diagnosis of Parkinson's disease had been establish in three periods (1985-1992, 1993-1999, and after July 2000, date of the national publication of the consensus) were constituted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">For these 3 groups, the initial treatment complied with the 2000 recommendations for 58, 84 and 82 percent of the patients respectively. The prescriptions of agonists increased progressively while the prescriptions of L-Dopa decreased for younger patients, in concordance with the consensus, but also for older patients, in opposition with the recommendations, though without any increase in the incidence of side effects. The non dopaminergic treatments were almost discarded as initial treatment.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Prescription habits have gradually changed over the past 10 years. Changes were linked to the elaboration of the national consensus conference guidelines and to the apparent desire to decrease L-Dopa prescriptions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Simonin</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Service de Neurologie et Pathologie du Mouvement, Clinique Neurologique, EA 2683, CHRU, Lille.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Defebvre</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Destée</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Traitement initial de la maladie de Parkinson: étude sur l'application des règles de consensus de mars 2000 dans la région Nord Pas-de-Calais.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Rev Neurol (Paris)</MedlineTA><NlmUniqueID>2984779R</NlmUniqueID><ISSNLinking>0035-3787</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003245" MajorTopicYN="N">Consensus Development Conferences as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019983" MajorTopicYN="N">Guideline Adherence</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>12</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15602362</ArticleId><ArticleId IdType="pii">MDOI-RN-12-2004-160-1-0035-3787-101019-ART04</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list></list><tree><noCountry><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name><name sortKey="Destee, A" sort="Destee, A" uniqKey="Destee A" first="A" last="Destée">A. Destée</name><name sortKey="Simonin, C" sort="Simonin, C" uniqKey="Simonin C" first="C" last="Simonin">C. Simonin</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E75 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000E75 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15602362
|texte= [Primary treatment of Parkinson's disease: the application of the March 2000 consensus rules in the Nord Pas-de-Calais area].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15602362" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |